DXCM : Insider Transactions for DexCom Inc

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

New Search

Get Insiders for :

DexCom Inc (DXCM)

$110.57

6.07 (5.2%) as of 4:30 Mon 6/24

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

389,580,000

Market Cap:

43.08(B)

Last Volume:

4,690,332

Avg Vol:

1,930,532

52 Week Range:

$75.49 - $140.45

Level I Sector:

Health Care

Level II Sector:

Health Services

Level III Sector:

Medical Instruments & Supplies

Member Indexes:

NASDAQ COMPOSITE

NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 487

Guru Rank Value : 3

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	71,005	274,979	309,595	581,627
Total Sell Value	$9,585,020	$36,298,507	$40,264,880	$70,726,419
Total People Sold	8	10	14	16
Total Sell Transactions	13	27	50	85
End Date	2024-03-24	2023-12-22	2023-06-23	2022-06-23

Adjust Filter Settings

Records found: 2309

Page 34 of 93

Filer's Name

Relation Title

Off-Dir-10%

Tran. Date

Form

Action

Price

Mkt Value

D/I

Shares

Holdings

Rank

3m +/-

Form

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-11-29

$60.12

$174,340

D/D

(2,900)

96,426

Balo Andrew K

EVP, Reg. Strategy, Clinical

• – –

2017-11-29

$60.00

$389,400

D/D

(6,490)

82,792

Foletta Mark G

Director

– • –

2017-11-27

$54.95

$137,386

I/I

(2,500)

13,143

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-11-24

$55.53

$90,788

I/I

(1,635)

18,880

Kahn Barbara

Director

– • –

2017-11-20

$54.58

$163,727

I/I

(3,000)

23,095

Sayer Kevin R

President & CEO

• • –

2017-11-20

$55.00

$660,000

D/D

(12,000)

286,826

Altman Steven R

Director

– • –

2017-11-07

$50.01

$1,250,250

I/I

25,000

58,502

2.1

Altman Steven R

Director

– • –

2017-11-06

$49.61

$496,100

I/I

10,000

33,502

2.1

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-10-23

$44.82

$73,274

I/I

(1,635)

20,515

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-09-25

$69.77

$114,080

I/I

(1,635)

22,150

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-09-25

$69.81

$101,219

D/D

(1,450)

99,326

Sayer Kevin R

President & CEO

• • –

2017-09-20

$69.34

$416,044

D/D

(6,000)

298,826

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-09-11

$71.81

$525,028

D/D

(7,311)

100,776

Sayer Kevin R

President & CEO

• • –

2017-09-11

$71.81

$1,138,530

D/D

(15,854)

304,826

Moy Jeffrey

SVP, Operations

• – –

2017-09-11

$71.81

$461,760

I/I

(6,430)

70,400

Moy Jeffrey

SVP, Operations

• – –

2017-09-11

$71.26

$866,949

I/I

12,166

76,830

Moy Jeffrey

SVP, Operations

• – –

2017-09-11

$71.26

$866,949

D/D

(12,166)

45,410

Murphy Patrick Michael

VP, Legal Aff & Chf Compl Ofcr

• – –

2017-09-11

$71.81

$94,937

D/D

(1,322)

33,131

Balo Andrew K

EVP, Reg. Strategy, Clinical

• – –

2017-09-11

$71.81

$540,827

D/D

(7,531)

89,282

Balo Andrew K

EVP, Reg. Strategy, Clinical

• – –

2017-09-11

$72.27

$234,441

D/D

(3,244)

96,813

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-09-11

$71.81

$540,827

D/D

(7,531)

65,049

Leach Jacob Steven

SVP, Research & Development

• – –

2017-09-11

$71.81

$455,441

D/D

(6,342)

75,919

Blackford Quentin S.

EVP, CFO, PFO & PAOOfficer

• – –

2017-09-07

$0.00

D/D

1,398

Blackford Quentin S.

EVP, CFO, PFO & PAO

• – –

2017-09-07

$0.00

$62

D/D

62,358

63,756

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-08-23

$75.26

$123,053

I/I

(1,635)

23,785

2309 Records found	Previous 30 31 32 33 34 35 36 37 38 39 Next	Page 34 of 93

Transaction Code Key:				Ownership Code Key
B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
OE	- Options Exercised	A	- Acquired
IO	- Initital Ownership	D	- Disposed

Summary:

Chart:

3m +/-: